Direkt zum Inhalt
Merck

naRNA-LL37 composite DAMPs define sterile NETs as self-propagating drivers of inflammation.

EMBO reports (2024-05-24)
Francesca Bork, Carsten L Greve, Christine Youn, Sirui Chen, Vinicius N C Leal, Yu Wang, Berenice Fischer, Masoud Nasri, Jule Focken, Jasmin Scheurer, Pujan Engels, Marissa Dubbelaar, Katharina Hipp, Baher Zalat, Andras Szolek, Meng-Jen Wu, Birgit Schittek, Stefanie Bugl, Thomas A Kufer, Markus W Löffler, Mathias Chamaillard, Julia Skokowa, Daniela Kramer, Nathan K Archer, Alexander N R Weber
ZUSAMMENFASSUNG

Neutrophil extracellular traps (NETs) are a key antimicrobial feature of cellular innate immunity mediated by polymorphonuclear neutrophils (PMNs). NETs counteract microbes but are also linked to inflammation in atherosclerosis, arthritis, or psoriasis by unknown mechanisms. Here, we report that NET-associated RNA (naRNA) stimulates further NET formation in naive PMNs via a unique TLR8-NLRP3 inflammasome-dependent pathway. Keratinocytes respond to naRNA with expression of psoriasis-related genes (e.g., IL17, IL36) via atypical NOD2-RIPK signaling. In vivo, naRNA drives temporary skin inflammation, which is drastically ameliorated by genetic ablation of RNA sensing. Unexpectedly, the naRNA-LL37 'composite damage-associated molecular pattern (DAMP)' is pre-stored in resting neutrophil granules, defining sterile NETs as inflammatory webs that amplify neutrophil activation. However, the activity of the naRNA-LL37 DAMP is transient and hence supposedly self-limiting under physiological conditions. Collectively, upon dysregulated NET release like in psoriasis, naRNA sensing may represent both a potential cause of disease and a new intervention target.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
PAD-Inhibitor, Cl-Amidin, Cl-amidine is a cell-permeable pan PAD inhibitor (IC₅₀ = 0.8, 6.2, and 5.9 µM for PAD1, PAD3, and PAD4, respectively). Inactivates the calcium bound form of PAD4 in an irreversible manner.